Developing therapies for Alzheimer's disease.
With the greying of the population, many more people will suffer from senile dementia, placing an enormous burden on families and on health provision. Alzheimer's disease, by far the most common form of dementia, is a complex disease, whose causes are still poorly understood despite a recent mushrooming in research. Many drugs are being developed that may provide symptomatic relief or slow down deterioration, but preventive therapies still seem a long way off.
Altman
J
J
D000109:Acetylcholine / Q000494:pharmacology / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000503:physiopathology* / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000378:metabolism; D001057:Apolipoproteins E / Q000235:genetics*; D001921:Brain / Q000378:metabolism / Q000473:pathology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007249:Inflammation; D013619:Tacrine / Q000494:pharmacology / Q000627:therapeutic use; D016875:tau Proteins / Q000378:metabolism
D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D002800:Cholinesterase Inhibitors; D016875:tau Proteins; D013619:Tacrine; D000109:Acetylcholine